ANI Pharmaceuticals Inc. (ANIP) Stock Price Up 3.2%
Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) rose 3.2% during trading on Tuesday . The company traded as high as $65.91 and last traded at $65.76, with a volume of 143,127 shares. The stock had previously closed at $63.75.
ANIP has been the subject of a number of recent research reports. Guggenheim reissued a “buy” rating and set a $80.00 price objective (up from $65.00) on shares of ANI Pharmaceuticals in a report on Friday, August 5th. Citigroup Inc. raised ANI Pharmaceuticals to an “outperform” rating and set a $65.00 price objective for the company in a report on Tuesday, July 19th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 price objective for the company in a report on Wednesday, July 20th. TheStreet raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 26th. Finally, Raymond James Financial Inc. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 price objective for the company. One analyst has rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $64.00.
The firm has a market capitalization of $749.79 million, a P/E ratio of 76.52 and a beta of 2.84. The stock’s 50-day moving average is $64.75 and its 200-day moving average is $52.16.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.34. The company had revenue of $31.30 million for the quarter, compared to analysts’ expectations of $27.63 million. ANI Pharmaceuticals had a return on equity of 20.12% and a net margin of 11.02%. ANI Pharmaceuticals’s quarterly revenue was up 60.5% on a year-over-year basis. During the same period last year, the firm earned $0.55 earnings per share. On average, equities research analysts anticipate that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current year.
In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 37,455 shares of the firm’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $66.97, for a total value of $2,508,361.35. Following the completion of the sale, the insider now directly owns 200,788 shares in the company, valued at $13,446,772.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert W. Schrepfer sold 12,500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the transaction, the vice president now owns 17,362 shares of the company’s stock, valued at $1,164,295.72. The disclosure for this sale can be found here. 31.60% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its position in ANI Pharmaceuticals by 94.9% in the second quarter. BNP Paribas Arbitrage SA now owns 2,364 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,151 shares during the last quarter. Bank of Montreal Can acquired a new position in ANI Pharmaceuticals during the second quarter valued at about $177,000. Thrivent Financial for Lutherans acquired a new position in ANI Pharmaceuticals during the second quarter valued at about $204,000. Arizona State Retirement System acquired a new position in ANI Pharmaceuticals during the second quarter valued at about $219,000. Finally, BlackRock Advisors LLC raised its position in ANI Pharmaceuticals by 6.1% in the second quarter. BlackRock Advisors LLC now owns 3,975 shares of the specialty pharmaceutical company’s stock valued at $222,000 after buying an additional 230 shares during the last quarter. Hedge funds and other institutional investors own 48.74% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.